Aug 11, 2020
MagVenture receives FDA clearance for OCD
Jun 08, 2020
NOCD Announces Results of a Clinical Trial on the Efficacy of its Mobile App Integrated with Exposure and Response Prevention for Treatment of Obsessive-Compulsive Disorder
May 21, 2020
Cigna Adds Talkspace To Its Rapidly-Expanding Virtual Provider Network
May 18, 2020
New Video from PANDAS Network Shows How Infections Attack Brains and Result in Devastating PANDAS/PANS Symptoms
Apr 01, 2020
Online Obsessive-Compulsive Disorder Therapy Provider NOCD Sees Therapy Sessions Double as COVID-19 Brings New Anxieties
Jan 24, 2020
Obsessive-Compulsive Disorder Therapeutic Landscape & Pipeline Review (2020, H1)
Oct 31, 2019
Promentis Pharmaceuticals Announces Positive Results for Phase 2A Study of SXC-2023 Targeting Novel Glutamatergic Mechanism and Completion of Enrollment for Phase 2 Trichotillomania Study
Oct 11, 2019
Rogers Miami Supports OCD Awareness Week With Community Awareness Event Hosted By OCD Central & South Florida
Oct 01, 2019
NOCD Raises $4 Million in Series A Funding
Sep 26, 2019
The Alex Manfull Memorial Fund: Supporting Research, Education and Treatment of PANDAS in Adolescents and Young Adults
May 13, 2019
Carolina Partners in Mental HealthCare Expands Treatment Offerings to Include Revolutionary Mental Health Technology for Obsessive-Compulsive Disorder in North Carolina
Apr 12, 2019
10 Questions Is All It Now Takes to Recognize Obsessive-Compulsive Disorder
Feb 26, 2019
Delray Center for Healing First in Florida to Treat Patients Suffering From Obsessive-Compulsive Disorder (OCD) with Deep Transcranial Magnetic Stimulation (Deep TMS)
Jan 17, 2019
Promentis Pharmaceuticals Announces Commencement of Phase 2 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism
Dec 18, 2018
Hope TMS Center Offering Obsessive-Compulsive Disorder (OCD) Treatment with BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS)
Dec 05, 2018
Promentis Pharmaceuticals to present at the 57th annual American College of Neuropsychopharmacology (ACNP) meeting
Nov 16, 2018
Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism
Nov 08, 2018
Psychiatry Northwest Now Offering Deep Transcranial Magnetic Stimulation (Deep TMS) for the Treatment of Obsessive-Compulsive Disorder (OCD)
Oct 19, 2018
Hair Loss Expert Lucinda Ellery Reveals Why We Need to Talk About Trichotillomania
Aug 17, 2018
FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder